Surveying the landscape

As the geneand cell therapy space becomes more crowded, DavidH Silverstein and Christopher M Gallosay that biopharmaceutical companies should turn to patent landscape analysis

David HSilverstein and Christopher M Gallo - Axinn,Veltrop & Harkrider

Academic and corporate labs have been engaged in research anddevelopment of gene and cell therapies for decades. But in the last 10 yearsthe commercial development and approval of these therapies has exploded.